L. Austin Doyle - Concepedia

Author

L. Austin Doyle

Also Known As

L A Doyle, L Austin Doyle, L DOYLE, L Doyle, L. A. Doyle, L. AUSTIN DOYLE, L. Austin Doyle, L. DOYLE, L. Doyle, L.A. Doyle

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute Wythenshawe Hospital National Institutes of Health The University of Texas MD Anderson Cancer Center Wayne State University

About

L. Austin Doyle is an author at National Cancer Institute specializing in medicine, oncology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	447
2	Arts	1	1	18
3	Language Studies	1	1	18
4	Allergy	1	1	13
5	Cell Biology	1	1	10

L. Austin Doyle

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study Anuradha Banerjee, Regina I. Jakacki, Arzu Onar‐Thomas, Neuro-Oncology	2017	309
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers Tanios Bekaii‐Saab, Mitch A. Phelps, Xiaobai Li, Journal of Clinical Oncology	2011	301
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson, The Lancet Oncology MedicineGemcitabine Versus GemcitabineMetronomic TherapyGynecologyCancer Treatment	2020	227
Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium Sonali M. Smith, Koen van Besien, Theodore Karrison, Journal of Clinical Oncology	2010	207
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial Gary K. Schwartz, William D. Tap, Li-Xuan Qin, The Lancet Oncology	2013	186
Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer Aung Naing, Razelle Kurzrock, Angelika M. Burger, Clinical Cancer Research	2011	116
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial Nitin Jain, Emily Curran, Neil M. Iyengar, Clinical Cancer Research	2013	111
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer C.A. Carter, Arun Rajan, Corrine Keen, Annals of Oncology	2016	89
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias Judith E. Karp, Benjamin D. Smith, Linda Resar, Blood	2011	80
Erythema and Desquamation After High-Dose Methotrexate L. Austin Doyle Annals of Internal Medicine Lymphoid NeoplasiaDiffuse Aggressive LymphomasLymphoma TreatedMedicineMalignant Blood Disorder	1983	77

Page 1